EASL 2017: Emerging Therapies for Genotype 3 HCV
Nancy Reau MD, FAASLD, AGAF - 5/12/2017
6 comments / Last Comment: 6/23/2017
Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.